all report title image
  • Published On : Aug 2022
  • Code : CMI5190
  • Industry : Pharmaceutical
  • Pages : 176
  • Formats :

Antibiotics, also known as antibacterials, are medications that destroy or slow down growth of bacteria in the body. Antibiotics include a range of powerful drugs, which are used to treat diseases caused by bacteria. Antibiotics can be a lifesaving treatment for children with bacterial infections and are the most commonly prescribed therapy among all medications given to children. Antibiotics cannot treat viral infections, such as cold, flu, and most coughs.

Global pediatric antibiotics market is estimated to be valued at US$ 6,478.9 million in 2022 and is expected to exhibit a CAGR of 2.3% during the forecast period (2022-2030).

Figure 1.Global Pediatric Antibiotics Market Share (%) in Terms of Value, By Route of Administration, 2022

Pediatric Antibiotics  | Coherent Market Insights

Increasing adoption of inorganic growth strategies by key players is expected to drive market growth during the forecast period.

Increasing adoption of inorganic growth strategies such as collaboration by key players for development of pediatric antibiotics is expected to drive the global pediatric antibiotics market growth over the forecast period. For instance, in April 2020, Venatorx Pharmaceuticals, a private, clinical-stage pharmaceutical company, and the Global Antibiotic Research and Development Partnership (GARDP), a not-for-profit research and development (R&D) organization,  announced a collaboration to accelerate development of, and access to, cefepime-taniborbactam (formerly cefepime/VNRX-5133). Cefepime-taniborbactam is an investigational combination of the fourth-generation antibiotic cefepime with taniborbactam, a novel, broad-spectrum beta-lactamase inhibitor that restores the activity of cefepime against carbapenem-resistant Enterobacterales (CRE) and carbapenem-resistant Pseudomonas aeruginosa (CRPA). GARDP will collaborate with Venatorx to complete development of cefepime-taniborbactam, which includes a phase 3 complicated urinary tract infection (cUTI) trial.

CMI table icon

Pediatric Antibiotics Market Report Coverage

Report Coverage Details
Base Year: 2021 Market Size in 2022: US$ 6,478.9 Mn
Historical Data for: 2017-2020 Forecast Period: 2022 to 2030
Forecast Period 2022 to 2030 CAGR: 2.3% 2030 Value Projection: US$ 7,759.3 Mn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC Countries, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Infection: Acute Sinusitis, Acute Otitis Media, Non-Specific Upper Respiratory Tract Infections, Urinary Tract Infections, OthersPlasmodium Vivax
  • By Route Of Administration: Oral, Topical, Intravenous, Others
  • By Distribution Channel: Distribution Channel: Hospital Pharmacies, Retail Pharmacies, E-CommercePrivate
Companies covered:

Johnson & Johnson, Astellas Pharma, Inc,  Pfizer Inc., Novartis AG, Bayer AG, Bristol-Myers Squibb Company, Abbott., DAIICHI SANKYO COMPANY, LIMITED, Dr. Reddy’s Laboratories Ltd, Teva Pharmaceuticals USA, Inc., Aurobindo Pharma USA, GlaxoSmithKline Plc., Hikma Pharmaceuticals PLC, Cipla Inc., Glenmark Pharmaceuticals, and Torrent Pharmaceuticals Ltd

Growth Drivers:
  • Increasing adoption of inorganic growth strategies by key players
  • Surge in prevalence of bacterial infections among children
Restraints & Challenges:
  • Side effects caused due to adverse reaction of certain antibiotics
  • Stringent regulations for the use of antibiotics in pediatrics

Figure 2.Global Pediatric Antibiotics Market Share (%), By Distribution Channel, 2022

Pediatric Antibiotics  | Coherent Market Insights

Surge in prevalence of bacterial infections among children is expected to drive market growth during the forecast period.

Surge in prevalence of bacterial infections among children is expected to drive global pediatric antibiotics market growth during the forecast period. For instance, according to data published by, UpToDate, Inc. a software system that is a point-of-care medical resource in July 2021, the overall prevalence of Urinary tract infections (UTI) is approximately 7% in febrile infants and young children but varies by age, sex, and circumcision status globally.

Global Pediatric Antibiotics Market– Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization had declared it a public health emergency. According to the World Health Organization’s report, the manifestation of coronavirus (COVID-19) has resulted in more than 535.8 million infected individuals worldwide as of June 17 2022.

COVID-19 had affected the economy in three main ways; by directly affecting production and demand of pediatric antibiotics, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries such as China, India, Saudi Arabia, UAE, Egypt, and others faced problems with regard to transportation of drugs from one place to another.

Furthermore, players operating in the global pediatric antibiotics market are facing major challenges on various fronts due to the COVID-19 pandemic. The major challenges include supply of raw materials required for manufacturing drug formulations due to irregularities in transportation. Moreover, distributors are experiencing irregular demand for products from the retailers due to an increase in the number of patients suffering from COVID-19

Global Pediatric Antibiotics Market: Restraint

The major factors that hinder growth of the global pediatric antibiotics market include side effects caused due to adverse reaction of certain antibiotics and stringent regulations for the use of antibiotics in pediatrics. Common side effects of antibiotics in pediatrics include diarrhea, allergic reaction which occurs when the immune system overreacts to something it views as dangerous, drug-related rash, yeast infection, stained teeth, and fever. Some severe side effects include anaphylaxis, Stevens-Johnson syndrome, toxic epidermal necrolysis, muscle pain, red man syndrome etc.

Key Players

Key players operating in market include Johnson & Johnson, Astellas Pharma, Inc,  Pfizer Inc., Novartis AG, Bayer AG, Bristol-Myers Squibb Company, Abbott., DAIICHI SANKYO COMPANY, LIMITED, Dr. Reddy’s Laboratories Ltd, Teva Pharmaceuticals USA, Inc., Aurobindo Pharma USA, GlaxoSmithKline Plc., Hikma Pharmaceuticals PLC, Cipla Inc., Glenmark Pharmaceuticals, and Torrent Pharmaceuticals Ltd.

Antibiotics are used to treat or prevent some types of bacterial infection. Antibiotics work by killing bacteria or preventing them from reproducing and spreading. Antibiotics are the most commonly prescribed drugs in children and have the potential to save the lives of patients with severe bacterial infections such as Non-Specific Upper Respiratory Tract Infections, Urinary Tract Infections etc. They are taken orally and come in the form of tablets, liquid suspension, and capsules. Antibiotics are also administered through the intravenous route. Antibiotics are available in the form of ointments, creams, lotions, etc. for topical administration.

Market Dynamics

Key players operating in the global pediatric antibiotics market are focusing on adoption of growth strategies such as product approval, which is expected to drive market growth during the forecast period. For instance, in January 2020, Merck a leading global biopharmaceutical company known as MSD outside of the U.S. and Canada, announced that the U.S. Food and Drug Administration (FDA) had approved a New Drug Application (NDA) for DIFICID (fidaxomicin) for oral suspension, and a supplemental New Drug Application (sNDA) for DIFICID tablets for the treatment of Clostridioides (formerly Clostridium) difficile-associated diarrhea (CDAD) in children aged six months and older. Moreover, increasing demand of pediatric antibiotics is expected to propel market growth over the forecast period. For instance, in 2021, United Nations International Children's Emergency Fund (UNICEF) delivered 31.6 million antibiotic treatments to children under one year of age in 54 countries.

 Key features of the study:

  • This report provides in-depth analysis of the global pediatric antibiotics market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global pediatric antibiotics market based on the following parameters – Company Highlights, Products Portfolio, Key Highlights, Financial Performance, Strategies
  • Key companies covered as a part of this study include Johnson & Johnson, Astellas Pharma, Inc,  Pfizer Inc., Novartis AG, Bayer AG, Bristol-Myers Squibb Company, Abbott., DAIICHI SANKYO COMPANY, LIMITED, Dr. Reddy’s Laboratories Ltd, Teva Pharmaceuticals USA, Inc., Aurobindo Pharma USA, GlaxoSmithKline Plc., Hikma Pharmaceuticals PLC, Cipla Inc., Glenmark Pharmaceuticals, and Torrent Pharmaceuticals Ltd. Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global pediatric antibiotics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global pediatric antibiotics market.

Detailed Segmentation:

  • Global Pediatric antibiotics Market, By Infection :
    • Acute Sinusitis
    • Acute Otitis Media
    • Non-Specific Upper Respiratory Tract Infections
    • Urinary Tract Infections
    • Others
  • Global Pediatric antibiotics Market, By Route of Administration :
    • Oral
    • Topical
    • Intravenous
    • Others
  • Global Pediatric antibiotics Market, By Distribution Channel :
    • Hospital Pharmacies
    • Retail Pharmacies
    • E-Commerce
  • Global Pediatric antibiotics Market, By Region:
    • North America
      • By Country
        • U.S.
        • Canada
    • Latin America
      • By Country
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Country
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Country
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Country
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Country
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • Johnson & Johnson.*
      • Company Highlights
      • Products Portfolio
      • Key Highlights
      • Financial Performance
      • Strategies
    • Astellas Pharma, Inc,
    • Pfizer Inc
    • Novartis AG
    •  Bayer AG
    •  Bristol-Myers Squibb Company
    •  Abbott
    •  DAIICHI SANKYO COMPANY, LIMITED
    • Dr. Reddy’s Laboratories Ltd
    • Teva Pharmaceuticals USA, Inc
    •  Aurobindo Pharma USA
    • GlaxoSmithKline Plc
    • Hikma Pharmaceuticals PLC
    •  Cipla Inc
    •  Glenmark Pharmaceuticals
    • Torrent Pharmaceuticals Ltd., etc.

“*” marked represents similar segmentation in other categories in the respective section.

Frequently Asked Questions

Global pediatric antibiotics market size is estimated to be valued at US$ 6,478.9 million in 2022 and is expected to exhibit a CAGR of 2.3% between 2022 and 2030
Factors such as increasing adoption of inorganic growth strategies by key players, and surge in prevalence of bacterial infections among children are expected to drive market growth over the forecast period.
Intravenous segment is expected to hold a major market share during the forecast period.
The major factors hampering growth of the market include side effects caused due to adverse reaction of certain antibiotics and stringent regulations for the use of antibiotics in pediatrics.
Major players operating in the market are Johnson & Johnson, Astellas Pharma, Inc,  Pfizer Inc., Novartis AG, Bayer AG, Bristol-Myers Squibb Company, Abbott., DAIICHI SANKYO COMPANY, LIMITED, Dr. Reddy’s Laboratories Ltd, Teva Pharmaceuticals USA, Inc., Aurobindo Pharma USA, GlaxoSmithKline Plc., Hikma Pharmaceuticals PLC, Cipla Inc., Glenmark Pharmaceuticals, and Torrent Pharmaceuticals Ltd.

Related Reports

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo